AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05803369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regulating Together (RT)
Description: Regulating Together is an intensive outpatient group treatment targeting emotion dysregulation. It engages both caregivers and children and utilizes evidence-based intervention techniques including cognitive behavioral therapy (CBT), visuals, reinforcements, and scaffolding, and newer interventions such as mindfulness and acceptance-based therapy.
Study NCT05803369 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Achieving Independence and Mastery in School (AIMS)
Description: AIMS is a school-based program developed to help students with social-communication challenges (such as autism spectrum disorder) achieve academic success. It is well-established and has been used with autistic youth, both in schools and in outpatient settings.
Study NCT06055127 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: osseodensifiction internal sinus lift / sticky bone graft material
Description: The osteotomy for the osseodensification internal sinus lift begins with a twist drill advanced at 800 rpm with saline irrigation to within 1-2 mm from the sinus floor. Next, a series of osteotomy drills are used in the same fashion at 800 rpm to widen the osteotomy. The final osteotomy drill is advanced with gentle pressure at 100 rpm counterclockwise without irrigation until a bouncing sensation occurs haptic feedback at this point infracture of the sinus has taken place. After infracture, injection of the graft material into the osteotomy site will occur. The final osteotomy drill is used to guide the graft apically. This process is repeated in an incremental fashion to lift the membrane. Once enough space has been created below the antral membrane, implant insertion will occur then suturing.
Study NCT06055127 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: piezoelectric internal sinus lift / sticky bone graft material
Description: In the PISE technique, an ultrasonic piezoelectric device (acteon), to which a specialized tip is attached, is used to break the sinus floor. Developed for sinus lift by the crestal approach, the Intralift™ Kit makes it possible to undertake dental non invasive surgery in full safety.~The diamond-coated tips, of increasing diameters (from 1.35mm to 2.80mm), are designed to drill and gradually widen the access canal to the sinus membrane. The sterile spray cools the tips down to avoid any rise in temperature, which could lead to oral tissue damage.The membrane elevation is achieved using the TKW5 by means of microcavitation. Thanks to the ultrasonic frequency modulation, the risk of membrane damage is limited. Moreover, the cavitation effect enables excellent visibility of the operating field.
Study NCT05491447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMX-010
Description: Ointment
Study NCT05491447 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ointment
Study NCT00012883 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Homewalking exercise program
Study NCT05594212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abdominal breathing training
Description: In the sleep center, it is carried out in a one-on-one manner by the trainer. At home, self-training through abdominal breathing training videos (10 minutes per day, you can accumulate up to 10 minutes in divided doses)
Study NCT06202001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab
Description: This study followed a classic 3+3 design, in which patients received escalating doses of TAS-102 (20, 25, 30, or 35 mg/m2/dose, administered twice daily for days 1-5) and irinotecan (135, 150, 165, or 180 mg/m2 on day 1) with a fixed dose of bevacizumab (5 mg/kg on day 1), repeated every 14 days.
Study NCT05649241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Description: Nicotine replacement therapy gum
Study NCT05649241 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Therapy Management
Description: Medication therapy management delivered by pharmacist - 1 in-person coaching session, and 5 follow-up telephonic coaching sessions.
Study NCT04740814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: * Pharmaceutical form: Solution for injection~* Route of administration: Subcutaneous Subjects will receive certolizumab pegol in a pre-specified sequence during the study.
Study NCT05737316 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combat PD
Description: CombatPD is an aerobic exercise programme hosted on a mobile application that pairs with motion sensors and heart rate monitor, which connects to a web-based portal for remote monitoring. The wearable sensors consist of (i) 2 motion sensors worn across one thigh and attached to an exercise ring which is held by the participant during the exergame and (ii) 1 heart rate sensor worn across the participant's chest. They will receive once weekly physiotherapy sessions at the study site for the first 4 weeks where they will be guided through the use of the CombatPD. Participants will be instructed to perform 2 sessions of 30-minute exergames in addition to a session of 30-minute brisk walking every week for 12 weeks at home. They will be instructed to exercise at a target heart rate zone at moderate intensity (i.e., 40% - 60% Heart Rate Reserve), which will be gradually increased.
Study NCT05737316 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants in the control group (usual care) will receive once weekly physiotherapy sessions for first 2 weeks and another session at week 6 where they will be taught home exercises based on a standard PD exercise booklet, consisting mainly of range of motion and stretching exercises , as well as brisk walking techniques. Participants in the control group will be instructed to perform these home exercises twice a week, in addition to a 30-minute brisk walk for 12 weeks.
Study NCT01288625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amifostine
Description: 500 mg sc, qod, 3 times per week
Study NCT01288625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifostine
Description: 500 mg sc, qod, 3 times per week
Study NCT01288625 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Amifostine
Description: 500mg rinsing wash, qod, 3 times per week
Study NCT01288625 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Amifostine
Description: 500mg rinsing wash, qod, 3 times per week
Study NCT05643248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEX-20A
Description: Subcutaneous prolonged-release injection
Study NCT05065307 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Venipuncture
Description: Diagnostic venipuncture
Study NCT05065307 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Venipuncture
Description: Diagnostic venipuncture
Study NCT05750316 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cowpea leaves mixed with Jam
Description: 6g of freeze-dried cowpea leaves, equivalent to 80g(a portion) of vegetables mixed with Jam and spread on bread
Study NCT05750316 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jam mixed with green food colour
Description: Jam with green food colouring spread on bread
Study NCT05506917 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: periodontal treatment
Description: Patients will receive an intensive (non surgical) regimen of scaling and root planing of the root surfaces under local analgesia (depending on the severity in one session or two sessions within 2 days). Any tooth that from the baseline examination is defined as hopeless or irrational to treat will be extracted at the oral hygiene visit. After the 2 months re-assessment individuals if presenting with at least one periodontal pocket of 6 mm in depth will undergo additional corrective periodontal therapy consisting of periodontal surgery and re-instrumentation under local analgesia. If surgical periodontal therapy is not indicated, appropriate re-instrumentation of the sites will be performed.
Study NCT04679441 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Computerized Functional Skills Assessment and Training Program
Description: The CFSAT program provides training on everyday tasks critical to independent living (e.g., financial and medication management). The program currently includes six domain simulations critical to independent living: ATM Banking/Financial Management, Online Banking, Prescription Refill via Voice Menu, Kiosk Ticket Purchase, Online Shopping (and prescription refill), and Medication Management.
Study NCT04679441 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Computerized Functional Skills Assessment and Training Program
Description: The CFSAT program provides training on everyday tasks critical to independent living (e.g., financial and medication management). The program currently includes six domain simulations critical to independent living: ATM Banking/Financial Management, Online Banking, Prescription Refill via Voice Menu, Kiosk Ticket Purchase, Online Shopping (and prescription refill), and Medication Management.
Study NCT04679441 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain HQ Double Decision
Description: Cognitive speed training program
Study NCT06317922 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thealoz Duo;
Description: THEALOZ DUO is a solution containing trehalose (3%), sodium hyaluronate (0.15%), sodium chloride, trometamol, hydrochloric acid, and water for injections; Hydraback is a solution containing a sodium chloride 0.9 %, sodium dihydrogen phosphate dihydrate, sodium phosphate dodecahydrate, water for preparations for injection.
Study NCT06317922 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham (Hydrabak)
Description: Hydrabak is an ophthalmic solution containing: sodium chloride 0.9%, sodium dihydrogen phosphate dihydrate, sodium phosphate dodecahydrate, and water for injectable preparations
Study NCT06527196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team Communication Training
Description: Participants in the experimental arm will receive enhanced Team Communication Training developed during Aim I of the trial. This will occur over a period of six months.
Study NCT06527196 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early Identification Universal Depression Screening
Description: Providers in the early identification universal depression screening condition will be asked to continue communications and response to depression screening as currently implemented.
Study NCT06528808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simple reality simulator application
Description: Women in the intervention group will be given an application aimed at breast cancer awareness with a simple valid simulator.
Study NCT05561894 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pulse pressure variation index guided fluid therapy
Description: maintainence intraoperative fluid therapy (ringer's acetate) will be given guided by either two goals of pulse pressure variation index, either >12% or >16%
Study NCT05561894 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pulse pressure variation index guided fluid therapy
Description: maintainence intraoperative fluid therapy (ringer's acetate) will be given guided by either two goals of pulse pressure variation index, either >12% or >16%
Study NCT05350540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICG dye
Description: Patients assigned to the intervention group will undergo surgery guided by tissue perfusion as directed by the ICG imaging
Study NCT06199024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral cinnamon supplementation
Description: In intervention group patients will take 1500 mg daily (3 tablets of cinnamon 500 mg, Sagepad Darou Pharmaceutical Company, Iran) that is, 4 weeks before the start of the new IVF cycle and 2 weeks during the ovarian stimulation process.
Study NCT06199024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oral cinnamon supplementation
Description: In intervention group patients will take 1500 mg daily (3 tablets of cinnamon 500 mg, Sagepad Darou Pharmaceutical Company, Iran) that is, 4 weeks before the start of the new IVF cycle and 2 weeks during the ovarian stimulation process.
Study NCT05497661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 448kilohertz Capacitive Resistive Radiofrequency Stimulation in a Sporty Population.
Description: 448kilohertz Capacitive Resistive Radiofrequency Stimulation on Patellar tendon in a Sporty Population.
Study NCT05497661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo comparator
Description: To simulate a 448kilohertz capacitive resistive monopolar radiofrequency application on the non dominant patellar tendon
Study NCT05497661 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: To simulate a 448kilohertz capacitive resistive monopolar radiofrequency application on the non dominant patellar tendon
Study NCT06261112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kaleidescope
Description: used to kaleideskope
Study NCT06279663 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Revascularization
Description: revascularization
Study NCT05279716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eybelis ophthalmic solution 0.002%
Description: Ophthalmic eye drop
Study NCT06270238 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Frequency1
Description: rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: ipsilateral primary motor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke.
Study NCT06270238 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cTBS1
Description: rTMS intervention: 40 seconds of cTBS at 70% RMT, totaling 600 pulses.~rTMS target: contralateral primary motor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke.
Study NCT06270238 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Frequency2
Description: rTMS intervention: 20 sessions of 10-Hz rTMS at 90% RMT, 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: ipsilateral premotor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke.
Study NCT06270238 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cTBS2
Description: rTMS intervention: 40 seconds of cTBS at 70% RMT, totaling 600 pulses.~rTMS target: contralateral primary motor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke.
Study NCT06270238 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Frequency3
Description: rTMS intervention: 20 sessions of 10-Hz rTMS at 90% RMT, 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: contralateral primary motor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke.
Study NCT06270238 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cTBS3
Description: rTMS intervention: 40 seconds of cTBS at 70% RMT, totaling 600 pulses.~rTMS target: contralateral primary motor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke.
Study NCT06492317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin
Description: Disitamab Vedotin: 2.5mg/kg, d1, ivdrip, Q2W (every 2 weeks)
Study NCT06492317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Cadonilimab: 6mg/kg, d1, ivdrip, Q2W (every 2 weeks)
Study NCT05344170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg Cannabinol (CBN)
Description: Participants will receive a 2 mL oral dose of 'ECS 310' (1.5%), an oral formulation of CBN (15 mg/mL) suspended in medium chain triglycerides (MCT) oil.
Study NCT05344170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 mg Cannabinol (CBN)
Description: Participants will receive a 2 mL oral dose of 'ECS 310' (15%), an oral formulation of CBN (150 mg/mL) suspended in medium chain triglycerides (MCT) oil.
Study NCT05344170 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a 2 mL oral dose of placebo. Placebo contains the same excipient, medium chain triglycerides (MCT) oil, as the investigational products but does not contain cannabinoids.
Study NCT05488730 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: passive leg raising test and fluid challenge
Description: Shocked patients were subjected to echocardiographic examination if (EF \<52%) .baseline LVOT VTI was obtained Then IVC scanning was done through subcostal Window and using M-mode the minimum and the maximum diameters were measured then the collapsibility index was calculated~Then passive leg raising test was done Patients who tolerated the PLR test and did not develop clinical or lung ultrasound signs of fluid overload (lung congestion) were given IV fluid bolus (250 ml normal saline) over 10 minutes followed by measurement of LVOT VTI.~Patients who did not tolerate PLR test or developed clinical or lung ultrasound signs of fluid overload (lung congestion) during PLR test were excluded from the third step (fluid challenge).~The differentiating factor used to allocate patient in which group (non-responder or responder) was LVOT VTI variability after fluid challenge (our gold standard to assess fluid responsiveness).
Study NCT05163236 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Positive fecal immunochemical test (FIT)
Description: We evaluated CRCs screening campaign from January 1, 2016 to December 31, 2017, and interval cancers within two years after a negative test, and five years for post-colonoscopy interval cancers.
Study NCT05163236 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Negative fecal immunochemical test (FIT)
Description: We evaluated CRCs screening campaign from January 1, 2016 to December 31, 2017, and interval cancers within two years after a negative test, and five years for post-colonoscopy interval cancers.
Study NCT05459441 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous progenitor expansion -T
Description: After the completion of RAK cell culture, RAK cells were slowly injected into the tumor cavity through Ommaya capsule for no less than 10 minutes, each time about 1.0-4.0 108/4 mL, once a week,3 times as a course of treatment. Il-2 (500,000 units/capsule) was injected into the tumor cavity through Ommaya reservoir every other day after the injection of RAK cells In other words, the day of RAK cell injection was the first day, and the third and fifth days were respectively injected. Then, about LML of sac fluid was pumped back before each injection to observe the growth of RAK cells in the tumor cavity. Il-2 was dissolved with LML normal saline, and the fluid storage sac was pressed 3-5 times after injection to make the sac fluid and IL-2 fully mixed.
Study NCT05163236 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fecal immunochemical test (FIT) not performed
Description: We evaluated CRCs screening campaign from January 1, 2016 to December 31, 2017, and interval cancers within two years after a negative test, and five years for post-colonoscopy interval cancers.
Study NCT05459441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: For patients with brain metastasis from solid tumor that met the inclusion conditions, the Ommaya capsule was placed 2 days later, and the maximum tolerated dose of pemetrexed intrathecal chemotherapy was injected intravaginally at 10mg according to the general situation of the patients and the results of the previous study.
Study NCT04581785 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hLB-001
Description: hLB-001 via IV infusion